Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

Friday, June 25, 2010

Majority of Surveyed Pharmacy Directors Expect to Look to Clinical Trial Endpoints When Evaluating the Relative Efficacy of MS Therapies

Pharmacy Directors are Most Convinced to Reimburse Multiple Sclerosis Drugs Supported by Data Showing Significant Reductions in Relapses


NASHVILLE, Tenn. and GLEN ROCK, N.J. June 24 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that surveyed pharmacy directors indicate a new multiple sclerosis (MS) treatment must demonstrate a reduction in the number and/or frequency of relapses in order to achieve equal reimbursement to current brands. According to the new Formulary Forum report entitled Formulary Advantages in Multiple SclerosisHow Will Price Impact the Uptake of Emerging Orally Delivered Therapies?, a reduction in relapses is important because of its two-fold effect on costs: reducing both prescription drug spending and the non-drug costs related to treatment, including diagnostic testing and follow-up office visits.

As pharmacy directors attempt to limit MS treatment-related costs, managed care organizations will increasingly look to clinical trial endpoints to evaluate the relative efficacy of MS therapies. Physicians frequently look for changes in a patient's score on clinical disability measures such as the Expanded Disability Status Scale or MS Functional Composite to evaluate an MS drug's efficacy in slowing disease progression.

"Surveyed pharmacy directors report non-prescription-drug spending for MS contributes as much, if not more, to total treatment costs as prescription drug spending," said Analyst MaryEllen Klusachek, Ph.D., author of the report. "With cost-containing efforts in mind, pharmacy directors will be evaluating a drug's ability to reduce the number or frequency of relapses, as well as its ability to delay disability progression when making reimbursement decisions, placing less emphasis on a new drug's minor side effect profile."

The new Formulary Forum report is based on a survey of 51 U.S. pharmacy directors who control formularies at national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary.

*
*
****************************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

Thursday, June 24, 2010

Nutra Pharma Begins Drug Registration Process In Central America For Its Nyloxin Pain Reliever

June 24, 2010
Nutra Pharma Has Begun the Drug Registration Process in Panama for Its Nyloxin Pain Reliever
Coral Springs, FL (Marketwire) - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that it has begun the drug registration process in Panama for its Nyloxin pain reliever.
"As an important international business center, Panama offers us an opportunity to introduce our Nyloxin pain reliever in Central America," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "We plan to move forward with this drug registration process in conjunction with finalizing our relationship with a prospective local distribution partner that has the resources and capabilities to successfully market and distribute Nyloxin throughout the country," he concluded.

*
*
****************************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

Wednesday, June 23, 2010

Sensors Help Multiple Sclerosis Patient Walk Without Falling

(Springfield) -- New technology is helping victims of multiple sclerosis, stroke or traumatic brain injury move around.

Bonnie Bell was diagnosed with multiple sclerosis 14 years ago. There's no cure for the disease but medication can slow the effects.

It took something larger than a pill, though, for Bell to stay on her feet.

At 50 years old, Bell says she won't be sidelined by M.S.

"I decided I was simply going to live life to the fullest," Bell says. "Whatever I needed to do in order to live every second of that life to the fullest, I was going to do."

But the ordinary act of walking became a burden.

"About four years ago I started needing the cane all the time," Bell says."

She has what doctors call a "foot drop."

"The messages from my brain telling the toe of my foot to raise, which yours does automatically without even thinking, just doesn't happen with mine," Bell says.

"Up here is the cuff," Cox Health physical therapist Chris Glenn says.

Technology called Bioness L-300 prevents the foot from dropping.

"This device will emit an electric current from the nerve into the muscle," Glenn says.

The cuff sends one message to the foot.

Continue reading a watch a video by clicking here

*
*
*****************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

Tuesday, June 22, 2010

Recommendation for treatment of progressive multifocal leukoencephalopathy (PML) with Natalizumab #ENS2010

Information provided by Penny in South Florida

June 21, 2010


In the name of the Medical Advisory Board of the German Multiple Sclerosis Society (Deutschen Multiple Sklerose Gesellschaft, DMSG), together with the neurological professional associations and in agreement with the Swiss and Austrian MS societies, Prof. Toyka and the board of directors have for the first time issued a recommendation on the use of the MS drug Natalizumab (Tysabri). The drug was withdrawn from the market in the US in 2005 and then reintroduced the following year. This was because patients contracted progressive multifocal leukoencephalopathy (PML), a serious and formerly often fatal virus infection of the central nervous system with severe neurological complications. The grounds for the recommendation were MS patients treated with Tysabri who then fell ill with PML. „All doctors treating MS patients with Natalizumab should have PML in mind if new neurological or psychiatric symptoms develop. Our specialists have worked out clear recommendations to ensure the safety of patients. First and foremost, every patient receiving treatment for a period of 24 months must once again be fully informed and monitored at very close intervals, should treatment be continued,“ says Prof. Toyka.

The German Multiple Sclerosis Society recommends magnetic resonance imaging as a first step in diagnosis. Should this not deliver definitive results, analysis of cerebrospinal fluid to ascertain the presence of the JC virus should be undertaken. Should this prove positive, the German Multiple Sclerosis Society and „Working group Immune Therapy“ initiated by Prof. Gold and other colleagues recommends plasmapheresis treatment „so that the active agent is eliminated from the body as quickly as possible.“

 „Despite the serious and grave risks, we consider there are still no grounds to generally limit treatment with Tysabri strictly to two years,“ says Prof. Toyka. „The expert group led by Prof. Wiendl is also of this opinion.“



*
*

************************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

Study shows people with Multiple Sclerosis can exercise more with breaks

study presented at a conference in San Antonio, Texas shows that people suffering from Multiple Sclerosis who take more rest breaks are able toexercise for longer periods of time.
The seemingly obvious results are significant, though, for people with the often debilitating neurological disease that creates exhaustion in patients, according to the study that was presented this week at the Consortium of Multiple Sclerosis Centers 24th Annual Conference and the Third Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis.

CLICK here to read full story
*
*
****************************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

YouTube - From service dog to SURFice dog - Inspirational video

Sent by Holly:
And Holly says to get a tissue ready

http://www.youtube.com/watch_popup?v=BGODurRfVv4



*
*
................................

Summer heat can cause the recurrence of MS symptoms

DALLAS, June 22 (UPI) -- Summer heat can cause the recurrence of MS symptoms for people with multiple sclerosis, a U.S. neurologist warns.

"Heat -- whether from infection, air temperature, prolonged exercise or even consuming hot liquids or foods -- can provoke the return of old MS-related symptoms such as numbness, stiffness, weakness or even vision loss," Dr. Elliot Frohman, director of the Multiple Sclerosis Program and the MS Clinical Center at the University of Texas Southwestern Medical Center in Dallas, says in a statement.

Researchers found the heat can slow down the speed of nerve messages for people with MS but heat alone does not cause a new attack or any additional nerve damage, Frohman says.

"Most patients can manage their heat sensitivity by avoiding situations that could be dangerous such as being out in severe heat without assistance, taking hot baths or showers, ingesting ice-cold beverages and, in some cases, drinking hot liquids like coffee and tea," Frohman adds


SOURCE: UPI

*
*

***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

Can multiple sclerosis attacks be minimized in a war zone?

June 21, 2010
Multiple sclerosis patients who directly confronted the stress of the Second Lebanon War suffered fewer attacks than those who chose to cope with the situation by focusing on feelings. This has been shown in a new study carried out by researchers of the University of Haifa, the Technion-Israel Institute of Technology and Carmel Medical Center. "Because there is no cure for multiple sclerosis to date, it is important to uncover all the factors that impact the recurrence of attacks," said Prof. Eli Somer of the University of Haifa, one of the authors of the study.

*
*


************************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************

LDN Updates for the UK and other places

The LDN TRUST just posted this information

June Updates can be found: http://www.ldnresearchtrustfiles.co.uk/docs/June%20Update.pdf


*
*
****************************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************